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Abstract
Background: Suicidal behaviour can be conceptualised as a continuum from suicidal ideation, to suicidal attempts to
completed suicide. In this study we identify genes contributing to suicidal behaviour in the depression study RADIANT.
Methodology/Principal Findings: A quantitative suicidality score was composed of two items from the SCAN interview. In
addition, the 251 depression cases with a history of serious suicide attempts were classified to form a discrete trait. The
quantitative trait was correlated with younger onset of depression and number of episodes of depression, but not with
gender. A genome-wide association study of 2,023 depression cases was performed to identify genes that may contribute
to suicidal behaviour. Two Munich depression studies were used as replication cohorts to test the most strongly associated
SNPs. No SNP was associated at genome-wide significance level. For the quantitative trait, evidence of association was
detected at GFRA1, a receptor for the neurotrophin GDRA (p = 2e-06). For the discrete trait of suicide attempt, SNPs in
KIAA1244 and RGS18 attained p-values of ,5e-6. None of these SNPs showed evidence for replication in the additional
cohorts tested. Candidate gene analysis provided some support for a polymorphism in NTRK2, which was previously
associated with suicidality.
Conclusions/Significance: This study provides a genome-wide assessment of possible genetic contribution to suicidal
behaviour in depression but indicates a genetic architecture of multiple genes with small effects. Large cohorts will be
required to dissect this further.
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Introduction
Suicide is a significant public health issue and a major cause of
death, with the WHO estimating that suicide accounts for 1.5% of
the deaths throughout the world. Attempted suicide is more
frequent than completed suicide (lifetime prevalence of ,3.5%),
and approximately 10% of suicide attempters will commit suicide
within 10 years [1]. Suicidal behaviour refers to the occurrence of
suicide attempts that range from completed suicide, to highly
lethal but failed suicide attempts, to suicide attempts of low
lethality [2]. Suicidal ideation comprises suicidal thoughts or
threats which may or may not be followed by action. Suicidality
can be viewed as a continuum of increasing severity from suicidal
ideation, to suicide attempts, to completed suicide [3]; [4]. Suicidal
behaviour is strongly linked with psychiatric disorders, in
particular, mood disorders and substance problems [5], with
approximately 90% of suicide attempters having a psychiatric
disorder.
Analyses from pooled twin studies of completed suicide showed
a higher concordance in monozygotic than dizygotic twins (11% v.
2%), with an estimated heritability of completed suicide of
approximately 43% (95% CI 27–60%), with no contribution from
shared family environment [6–8]. Such studies of the familiality of
completed suicide are limited by the small numbers, but indicate
the existence of genes contributing to suicidal behaviour. Many
family studies have shown an increase in suicidal behaviour,
showing a high familiality of both attempted and completed
suicide [9]. Such familial transmission of suicidal behaviour is not
fully explained by co-morbid psychiatric disorders, and may be
more closely related to aggression and impulsivity traits transmit-
ted within the family [10]. Twin studies which extended the
phenotype to suicidal ideation found some overlap of genetic
contribution to suicidal ideation and suicidal attempts [8]. These
studies together indicate that a broad spectrum of suicidal
behaviour is likely to be partly under genetic control, and that
part of the genetic contribution is independent of that for
psychiatric disorder.
Although the existence of genetic vulnerability to suicidality is
well-established, progress in the identification of its molecular basis
has been slow. Functional candidate gene studies have identified
few replicable associations and other candidate genes have been
identified through expression studies [11]; [12]. More recently, a
genome-wide association study on suicide attempt in mood
disorder subjects found suggestive evidence for multiple loci that
needs to be replicated [13]. The genetic contribution to treatment-
emergent suicidal ideation (TESI) during antidepressant treatment
has also been investigated [14,15].
In this study, we investigate a broad phenotype of suicidal
behaviour, a term we use here to encompass both suicidal ideation
and suicidal attempts, in cases of major depressive disorder
(MDD). Analyzing suicidal behaviour in a cohort of depression
cases provides an a priori high risk group for suicidal behaviour that
is appropriate for uncovering the genetic contribution to this
complex phenotype. We defined a quantitative suicidality measure
in depression cases from the RADIANT study, and established its
correlation with other features of major depression. Through the
use of suicidality as a continuum from ideation to suicide attempts
as a quantitative trait, we aim to increase power to detect genes
associated with suicidality. We also consider the trait of suicide
attempt, which forms the upper tail of this quantitative trait. Since
this is a retrospective study, with suicidality assessed by recall of the
most severe episode of depression, the most severe end of spectrum
(i.e. completed suicide) will be missing. To identify genes that
underlie suicidality, we performed a GWAS and further
investigated candidate genes previously implicated in susceptibility
to suicidality. Regions showing strongest evidence for association
were tested in two additional cohorts of depression cases from
Munich (MARS, GSK-Munich) as a replication study.
Results
We defined a continuous SCAN Suicidality (SSU) score using
responses from two items in the SCAN questionnaire in the
RADIANT studies, which comprise DeCC (cases ascertained in
the UK), DeNt (cases ascertained across Europe) and a cohort
from Bonn/Lausanne (ascertained in collaboration with GSK).
SSU scores capture the distribution of suicidality in MDD cases
from ideation to suicide attempt, and were available in a total of
Table 1. Distribution of SSU score and study characteristics.
Study
No.
individuals
Mean SSU
score (s.d.)
No. with suicide
attempts (%)
No. females
(%)
Mean age
onset, s.d. (years )
Mean age at
interview, s.d. (years)
DeCC 1117 3.857 (1.639) 125 (11.3%) 767 (69.2%) 23.0 (11.6) 47.1 (12.0)
DeNt 898 3.867 (1.687) 125 (14.0%) 686 (77.1%) 21.9 (11.2) 44.9 (11.7)
Bonn/Lausanne 163 3.568 (1.652) 15 (9.7%) 115 (74.2%) 25.3 (12.8) 49.7 (12.5)
Total 2154 3.84 (1.661) 265 (12.3%) 1568 (72.8%) 22.7(11.5) 46.3 (12.0)
doi:10.1371/journal.pone.0020690.t001
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2154 depression cases (2023 of which also met QC for genome-
wide association) (Table 1). SSU scores were similar in DeCC
(mean SSU score of 3.86), DeNt (mean SSU score = 3.87), and the
Bonn/Lausanne samples (mean SSU=3.57). The SSU score was
symmetrically distributed, with 45.2% of cases having a score of 4.
There was a high correlation between SSU scores in the subject’s
reported worst and second worst episode of depression, with
50.1% of cases having equal scores in both episodes, and 38.4%
having a higher SSU score in the worst episode.
SSU score was significantly associated with the number of
depressive episodes (p,261026) and age at onset (p = 0.004), but
not with sex (p= 0.72). The mean SSU score for cases with two
episodes of depression was 3.7 compared to 3.9 for cases with three
or more episodes (p = 0.007). Younger age of onset predicted
higher SSU scores in the cases from the DeCC study (which were
ascertained on the basis of recurrent depression only)
(p = 9.761025), but not in the DeNt study (p = 0.875), where
cases additionally had a sibling with recurrent depression. These
differences are not accounted by differences in mean ages of onset
or SSU scores in these studies (Table 1).
There was a significant association between SSU score and
Beck’s Depression Inventory score (p,1028), with higher BDI
scores predicting higher SSU scores. Personality traits were
assessed using the Eysenck Personality Questionnaire (EPQ) in
all studies. There was a significant association of both EPQ-
extroversion (EPQ-E) score (p,1028), and EPQ-neuroticism
(EPQ-N) (p,1028) with SSU score. Individuals with higher
EPQ-E scores had significantly lower SSU scores, whereas
individuals with higher EPQ-N scores had significantly higher
SSU scores.
The SCAN questions enable us to classify MDD cases as having
made a serious attempt at suicide in their depressive episode.
These cases lie in the upper tail of the SSU score, and 12.3% of
depression cases were classified as having made a serious suicide
attempt in the discrete SSU trait. The mean SSU score for the
suicide attempters was 6.68, compared to 3.16 for the non-suicide
attempters. These groups did not differ by sex, age at onset of
depression or age at interview.
In the GSK-Munich replication cohort, SCAN information was
available on 982 cases of recurrent depression. The distribution of
SSU score was similar to RADIANT, with 47.8% of cases having
a score of 4 (Figure 1). Similar correlations with clinical covariates
were obtained as in RADIANT: SSU score was significantly
correlated with age (p= 1.37e-05), but not with sex (p= 0.312). In
total, 13.1% of 982 depression cases scored .5 on the SSU score
and were therefore classified as making a suicide attempt. This
figure is comparable with the 12.3% prevalence of suicide attempt
in RADIANT, which had similar ascertainment criteria.
In the MARS replication cohort, 20.9% of 532 depression cases
reported a suicide attempt; no quantitative trait information,
equivalent to that from SCAN, was available. The prevalence of
suicide attempt is substantially higher than in RADIANT or the
GSK-Munich cohorts, which reflects the different definitions of
lifetime suicide attempts (MARS) or suicidal behaviour in the two
worst episodes of depression (RADIANT, GSK-Munich).
Genome-wide association study
No SNP was associated with suicidal behaviour at the genome-
wide level of significance (p= 561028) in the analysis of either the
quantitative SSU score or the discrete trait of suicide attempt
Figure 1. Distribution of SSU score, by study.
doi:10.1371/journal.pone.0020690.g001
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(Figure 2). Seven SNPs from three regions showed significance at
our suggestive level of significance (p= 561026; Table 2). In the
analysis of quantitative SSU score, rs4751955 on chromosome 10
achieved a p-value of 7.5761027. This SNP is located in an intron
of GFRA1, the GDNF-family receptor alpha 1 gene. The most
significant result for the discrete trait of serious suicidal attempts was
at rs203136 (p= 1.9161027) in gene KIAA1244 on chromosome
6q23.3, which encodes the brefeldin A-inhibited guanine nucleo-
tide-exchange protein 3 (BIG3). Four SNPs on chromosome 1 also
reached suggestive significance in the analysis of the discrete trait
(the most significant SNP is listed in Table 2), These SNPs lie in an
1.6 Mb gene desert between RGS18 (which encodes a member of
the regulator of G-protein signalling family) and FAM5C (family
with sequence similarity 5, member C). The most significant results
in the quantitative and discrete SSU score traits did not occur at the
same SNPs, but there was strong consistency between results
overall, as expected since the discrete SSU score is defined by the
upper tail of the quantitative distribution. A p-value of ,0.05 was
attained at 27,186 SNPs in the quantitative analysis, and 27,852
SNPs with the discrete trait. Of these, 7707 (28%) were common to
both analyses, and all SNPs had effect sizes in the same direction.
In the two Munich replication cohorts, no evidence for
association was found at the top SNPs in the RADIANT study
for either the quantitative trait of suicidal behaviour (GSK-
Munich study) or the discrete suicide attempt trait (GSK-Munich,
MARS) (Table 2). One other genome-wide study of suicide
attempts in MDD has been published, using cases from the
STAR*D trial (13). We performed a meta-analysis of the strongest
results from that study and RADIANT. The SNPs showed no
consistent replication in RADIANT, with the strongest evidence
for association (p = 0.0010) arising at rs1377287, located in an
intron of the solute carrier family 4, member 4 gene, SLC4A4
(Table 3). Although the OR estimates for Munich studies MARS
and GSK are in the same direction at the RADIANT effect at
rs1377287 (OR=0.823, 0.861), the p-values add little support to
the results, and a meta-analysis across studies decreased in
significance (Fisher’s method meta-analysis p-value = 661025).
Candidate gene analyses
We tested for association with a set of 33 candidate genes (875
SNPs) previously implicated in susceptibility to suicidality through
their function or previous genetic association studies. No strongly
significant results were obtained for SNPs in any candidate gene.
Table 4 lists the genes in which at least one SNP achieved p-
value,0.01 in the quantitative or discrete SSU trait, and a
correction for multiple testing of SNPs within the gene (only the
most significant SNP for each gene is shown). None of these
findings would survive an additional correction for multiple testing
across the number of genes analysed. Three SNPs achieved
nominal significance: HTR1A in the trait of suicide attempts, CCK
and RSG18 in the association with quantitative SSU trait, but none
of these were associated in the Munich cohorts. Two SNPs, in
NTRK2 and SCN8A achieve nominally significant p-values (,0.05)
in Munich cohorts, but with opposite direction of association to
RADIANT. The NTRK2 SNP, rs10868235, associated with
suicide attempts in the German depression cases and has already
been reported in the Munich cohorts [16].
Discussion
We carried out a GWAS of suicidality in 2023 subjects with
DSM-IV and/or ICD-10 diagnosis of MDD in the RADIANT
Figure 2. Summary of results for the quantitative suicidality trait (SSU) and the discrete trait of suicide attempt, showing quantile-
quantile plots and Manhattan plots. Genomic control l values were 1.007 (SSU score) and 1.012 (discrete trait).
doi:10.1371/journal.pone.0020690.g002
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studies. No genome-wide evidence of association was detected for
either suicidality measure analysed. SNPs in three genetic regions
reached our threshold for suggestive evidence of association: in
GFRA1, when analysing suicidality as a quantitative trait and two
regions (in KIAA1244, and between RGS18 and FAM5C) when
analysing the discrete trait of suicide attempt. GFRA1 is a receptor
of the neurotrophin GDNF which has been widely investigated in
mood disorders (MDD and bipolar disorder), schizophrenia and
treatment responses [17]; [18]; [19]; [20]). Another GDNF
receptor gene, GFRA2, has been associated with antipsychotic
response in a GWAS [21]. Given BDNF’s reported involvement in
suicidal behaviour [22]; [23], these new results implicating GDNF
and its receptor suggest that neurotrophic systems play a role in
suicidal behaviour, possibly through an inability of neuronal
systems to exhibit appropriate adaptive plasticity.
The location of the strongest association signal within a gene of
high potential relevance to psychiatric disorders (GFRA1) increases
the probability that these findings may be true but modest signals
of association. However, none of the SNPs showing evidence for
association in the RADIANT study were significantly associated
with SSU or with suicide attempt in the Munich GSK and MARS
studies. This lack of replication is not unsurprising in a complex
phenotype such as suicidal behaviour where the genetic contribu-
tion is likely comprise small effects. A recent meta-analysis of
genetic association with suicide attempts in bipolar disorder and
MDD also failed to show replication across the different studies
included [13]. In the STAR*D depression study, they showed
genome-wide significance for SNPs in AB13BP, which did not
replicate in their replication cohort of the NESTA/NTR. Meta-
analysis of SNPs associated with suicide attempts in STAR*D with
results from RADIANT failed to identify SNPs with suggestive
evidence of association. Meta-analysis across large samples with
homogeneous definitions of suicide behaviour and, possibly,
underlying psychiatric disorder will be required for further
dissection of the genetic contribution to suicidality.
In our analysis of candidate genes for suicidal behaviour, three
of the top associations survived a correction for multiple testing of
SNPs within the gene, but fell short of the required significance for
multiple testing across genes. For HTR1A, our associated SNP is in
low linkage disequilibrium with a SNP, rs6295, previous suggested
to be associated with suicide attempt [24]. In RGS2, the associated
SNP in our analysis was not in linkage disequilibrium with the two
SNPs reported as associated with suicidality in a Japanese
population [25]. Similarly, in CCK (cholecystokinin) an association
was observed at 2196G/A in male Japanese suicide attempters,
which has not been replicated further [26]. LD between this
variant and our associated SNP is unknown.
The current study has several limitations. First of all, the SCAN
SSU score was defined from two items of the depression section of
the SCAN interview. Neither the instrument nor our depression
studies were designed primarily to address suicidality. The validity
of the score assumes a consistency across the two SCAN items used
in its definition: i.e. that an increase of one score point in the
question on suicidal ideation is equivalent to an increase in one
score point in suicidal action, and that within each question, the
responses have a linear relationship with increasing severity of
suicidality. Our sample of MDD cases had good power to detect
genes of moderate effect size, but had limited power to identify
genes of small effect size that are assumed to be involved in suicidal
behaviour. Therefore, it is likely that the reported findings are false
positives, as implied by the lack of replication in the two additional
cohorts. Our investigation was performed within a single disorder
(major depression) which could be seen as a limitation of this
study. However, focusing on suicidal behaviour within a single
disorder allows the distinction between genes relating to suicide per
se from those associated with the disorder itself (major depression)
[15,27].
In conclusion, we have performed a GWAS for suicidality
encompassing both ideation and behaviour in MDD. We failed to
detect evidence for association at a genome-wide level of
significance, and the strongest results in our study were not
replicated in analysis of independent MDD cohorts with a similar
assessment of suicidal behaviour. Further attempts to replicate
these findings will be necessary to determine whether the
Table 3. Comparison of most significant results from GWAS of suicide attempts in STAR*D [13], showing p-values from RADIANT
study, and meta-analysis p-values using Fisher’s method.
STAR*D RADIANT
SNP CHR
Base pair
position
Closest
Gene Alleles OR p-value
Tested
allele OR p-value
Fisher’s method
p-value
rs1377287 4 72355439 SLC4A4 AG 0.536 0.00030 G 0.556 0.0010 4.870E-06
rs276420 13 39470070 COG6 GT 0.666 0.00043 T 0.759 0.0048 2.956E-05
rs7339164 13 39470053 COG6 AG 1.567 0.00013 A 0.763 0.0081 1.541E-05
rs3734662 6 90707807 BACH2 CT 0.664 0.00083 C 0.779 0.0110 1.149E-04
rs9603665 13 39500347 COG6 CT 0.680 0.00091 T 0.772 0.0113 1.287E-04
rs1777077 14 42258660 LRFN5 CT 1.628 0.00085 C 1.303 0.0165 1.704E-04
rs7941624 11 80658536 MGC33846 AG 1.830 0.00077 G 0.739 0.0173 1.620E-04
rs6966472 7 84537323 SEMA3D CT 1.834 0.00019 C 1.358 0.0189 4.754E-05
rs10897779 11 80661868 MGC33846 GT 1.661 0.00099 T 0.753 0.0222 2.573E-04
rs10890590 11 106171269 GUCY1A2 AG 0.573 0.00046 A 0.777 0.0257 1.460E-04
rs17459015 6 104924468 HACE1 CT 1.636 0.00051 C 1.292 0.0263 1.631E-04
rs2240394 7 84530877 SEMA3D CT 1.718 0.00044 C 1.332 0.0282 1.516E-04
rs1409470 13 104284951 DAOA AG 0.643 0.00026 G 1.227 0.0340 1.127E-04
rs270678 6 104891512 HACE1 CT 1.645 0.00045 C 1.274 0.0356 1.943E-04
doi:10.1371/journal.pone.0020690.t003
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suggestive signals detected in this study are true effects or false
positives.
Materials and Methods
Ethics Statement
All participants in this study gave written informed consent. The
study was approved by the local Ethics Committee at the Institute
of Psychiatry, King’s College London.
Samples
MDD cases from the RADIANT studies DeCC and DeNt with
information on suicidal ideation and suicide attempts while in a
depressive episode were analysed. The DeCC (Depression Case
Control) sample consists of 1346 cases (69.3% women) of recurrent
depression fulfilling DSM-IV and/or ICD-10 criteria of at least
moderate severity ascertained from three UK clinical sites
(London, Cardiff and Birmingham) [28]. The mean age of onset
was 22.9 years (SD 10.8 years). Subjects were identified from
psychiatric clinics, hospitals, general medical practices, and from
volunteers responding to media advertisements. Retrospective
information on the subject’s two most severe episodes of
depression was collected using Schedules for Clinical Assessment
in Neuropsychiatry SCAN [29], which includes two questions on
suicidal ideation and behavior.
The DeNt (Depression Network) affected sibling pair linkage
study [30], [31] comprises cases of recurrent depression of at least
moderate severity. Subjects were ascertained from three UK sites
(London, Cardiff and Birmingham), four other European sites
(Aarhus, Bonn, Dublin and Lausanne) and a site in St. Louis,
USA. Only the proband from each family, for whom genome-wide
genotypes were available, was included in the phenotype and
genotype analysis presented here (n = 898). As in DeCC, symptom
type and severity for the subject’s worst and second-worst episode
of depression were assessed using the SCAN interview. An
additional 163 cases of recurrent depression collected in Bonn
and Lausanne, using exactly the same protocol as the DeNt study,
were also analysed.
All cases from all studies fulfilled DSM-IV and/or ICD-10
criteria of at least moderate severity. Study co-ordinators for all
studies were trained by A.E.F. ensuring homogeneity of clinical
data collected. Exclusion criteria across studies were broadly
comparable. Subjects were excluded if there was a history or
family history of schizophrenia or bipolar disorder, for mood-
incongruent psychosis, or if mood symptoms were related to
alcohol or substance misuse. All study participants completed the
Beck’s Depression Inventory (BDI) and the Eysenck Personality
Questionnaire (EPQ).
Suicidality phenotype
A new variable named SCAN SUcidality (SSU) score was created
in RADIANT. This measure combines responses to two SCAN
items: 6.012, which assesses tedium vitae, and 6.011, which rates
suicide attempt and self-harm during the episode of depression. In
6.011, a score for suicide attempt and self-harm between 0 and 4 is
assigned, on the scale 0: absent; 1: deliberately considered suicide or
self-injury but made no attempt; 2: injured self or made an attempt
but no serious harm results; 3; as 2. but with serious self-harm; 4:
made an attempt at suicide designed to result in death. Question
6.012, which is only included when the response to 6.011 score is 0,
is scored at between 0 and 3, assessing response to the question
‘Have you felt that life was not worth living or that you would not
care if you didn’t wake in the morning?’ For a non-zero score on
6.011, the SSU score was defined equal to the 6.011-score+3 (giving
integer scores of 4, 5, 6, 7). Where the 6.011 score was zero, the SSU
score was defined equal to the 6.012 (tedium vitae) score, giving values
of 0 to 3. The SSU algorithm allows action (6.011) to ‘‘trump’’
ideation (6.012), and gives a distribution of integer-valued scores of
between 0 and 7. SCAN information for both the worst and second-
worst episode of depression were analysed, and the maximum SSU
score was used.
Serious suicidal attempts were defined as an SSU score of 6 or
more, corresponding to a suicide attempt ‘‘with serious harm’’ or
‘‘an attempt at suicide designed to result in death’’ (that is, a score
of 3 or 4 on SCAN item 6.011).
Genotyping
DNA was extracted as described previously. Concentrations of
all samples were adjusted to 50 ng/ml and 15 ml of each robotically
dispensed into barcoded 96-well plates. Concentration, fragmen-
tation and response to PCR were determined. Whole-genome
genotyping was performed using the Illumina HumanHap610-
Quad BeadChip by the Centre National de Ge´notypage (CNG),
France. All DNA samples were subjected to stringent quality
control, and processing was carried out under full LIMS control.
The raw data were analysed using GTS Image and extracted for
statistical analysis.
Quality control
Stringent quality control procedures were applied to individual
and SNP data. Individuals were excluded if their genotypic data
showed missing rate .1%, abnormal heterozygosity, a sex
assignment that conflicted with phenotypic data, if they were
related (up to 2nd degree) with other study members, or of non-
European ancestry. Non-European ancestry was determined using
principal components analysis of HapMap CEU, JPT, CHB, YRI
and GIH populations with EIGENSTRAT [32]. Related or
duplicate cases were identified through identity-by-state sharing
analysis; for each pair related up to second degree relationships, the
individual with lower genotyping completeness was omitted. SNPs
with minor allele frequency ,1% or showing departure from
Hardy-Weinberg equilibrium (p,161025) were excluded. EIGEN-
STRAT analysis was performed again after QC procedures, and
five ancestry-informative principal components (PCs) were used as
covariates in association testing. For further details of quality control
see Lewis et al. [33]. The final data set comprised 2023 depression
cases with quantitative SSU scores (including 251 cases with suicide
attempt) which were genotyped on 532,774 SNPs.
Statistical analysis
The relationship between the quantitative SSU trait and
relevant covariates (study, sex, age of onset, number of depressive
episodes) was determined using linear regression and binomial
tests. The quantitative SSU score (which lies on an ordinal scale of
0–7) was treated as a continuous variable. In the genetic analysis,
association between SNPs and suicidality in MDD was tested using
linear regression for the quantitative SSU score and logistic
regression for the discrete trait, assuming a log-additive model for
SNP genotype. In all analyses, five ancestry-informative principal
components were included as covariates. The genomic control
parameter l was calculated for each analysis to assess test statistic
inflation due to residual population stratification [34]. Genomic
control l values were 1.007 (SSU score) and 1.012 (for the discrete
trait), indicating no inflation of test statistics from uncorrected
population stratification or other systematic bias. Analyses were
implemented using PLINK 1.07 [35] and R (www.r-project.org).
Two thresholds of significance were used to interpret association
results: genome-wide evidence for association at a p-value
GWAS of Suicidal Behaviour in Major Depression
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threshold of 561028 [36] and suggestive evidence of association,
set two orders of magnitude lower, at p,561026. These
thresholds provide appropriate correction for multiple testing of
SNPs across the genome; no additional correction was made for
analysis of two phenotypes. The power of the study to detect
association was calculated assuming a continuous quantitative
trait, using Genetic Power Calculator (GPC, [37]). For a SNP
accounting for 1.5% of additive genetic variance, 2023 individuals
gives approximately 83% power to detect association at the
suggestive level of significance, and 53% power at genome-wide
level of significance. For the discrete trait (251 suicide attempt
cases, 1772 controls), this study had 85% power at suggestive level
of significance (and 56% power at genome-wide significance) to
detect a SNP of frequency 0.3 conferring a genotype relative risk of
1.6 under a log-additive model.
We also tested specifically for association with a set of 33
candidate genes previously implicated in susceptibility to suicid-
ality through their function or previous genetic association studies
(Table S1) [14]. In total, 875 SNPs lying in the genes or in 20 kb
flanking regions were tested. Multiple testing correction for SNPs
within genes was used the web-based SNPSpD software (http://
gump.qimr.edu.au/general/daleN/SNPSpD) which estimates the
number of independent tests (Meff), accounting for LD between
genotyped SNPs [38]; [39]. A gene-wide threshold for significance
was then calculated as acorr = 0.05/Meff. No correction for multiple
testing across genes was applied.
Replication study
Replication of the top SNPs associated with the SSU score and
suicide attempt discrete traits was performed in two MDD cohorts
from Germany. The GSK-Munich cohort [40] was collected using
identical measurement instruments to the RADIANT study, with
investigators trained by A.E.F. This cohort comprises 982 cases
with information on the SCAN and genoytped on the Illumina
550K platform. From the Munich Antidepressant Response
Signature (MARS) project, 549 cases of depression genotyped on
the Illumina 610K platform were available [41][42]. Lifetime
history of suicide attempt was determined in a semi-structured
clinical interview as part of the MARS study and from the suicide
item on the Hamilton Scale for Depression rating scale. Standard
genotype QC procedures were applied, and no correction was
necessary for population stratification. Analysis of the quantitative
SSU score (GSK-Munich only) and the discrete suicide attempt
variable (both cohorts) was performed as in the RADIANT study.
Meta-analysis of top hits from RADIANT was performed using
PLINK under a fixed effects model. We also tested for replication
to SNPs that were associated with suicide attempt in 1,273
depression cases in the STAR*D study [43]. Meta-analysis of
SNPs with association p-values of ,0.001 (listed in Supplementary
Table 2 of Perlis et al. [13]) which were also genotyped in our
studies (n = 323) was performed using Fisher’s method for
combining p-values.
Supporting Information
Table S1 List of candidate genes and their rationale for
their inclusion.
(DOCX)
Author Contributions
Conceived and designed the experiments: P. McGuffin CML AEF IWC
GB. Performed the experiments: SC-W. Analyzed the data: CML AWB
MYN NP RU AS BM-M MI. Contributed reagents/materials/analysis
tools: NC MJO AK LJ IJ MG JPR WM OM MR MP JP FT P. Muglia
KJA EBB SL. Wrote the paper: AS CML NP RU IWC P. McGuffin AEF
GB.
References
1. Suominen K, Isometsa E, Suokas J, Haukka J, Achte K, et al. (2004) Completed
suicide after a suicide attempt: a 37-year follow-up study. Am J Psychiatry 161:
562–563.
2. Mann JJ (2002) A current perspective of suicide and attempted suicide. Ann
Intern Med 136: 302–311.
3. Courtet P, Jollant F, Castelnau D, Buresi C, Malafosse A (2005) Suicidal
behavior: relationship between phenotype and serotonergic genotype. Am J Med
Genet C Semin Med Genet 133C: 25–33.
4. Perroud N, Uher R, Hauser J, Rietschel M, Henigsberg N, et al. (2010) History
of suicide attempts among patients with depression in the GENDEP project.
J Affect Disord 123: 131–137.
5. Arsenault-Lapierre G, Kim C, Turecki G (2004) Psychiatric diagnoses in 3275
suicides: A meta-analysis. BMC Psychiatry Vol4 Nov 2004, ArtID 37 11.
6. Roy A, Segal NL, Centerwall BS, Robinette CD (1991) Suicide in twins. Arch
Gen Psychiatry 48: 29–32.
7. McGuffin P, Marusic A, Farmer A (2001) What can psychiatric genetics offer
suicidology? Crisis 22: 61–65.
8. Fu Q, Heath AC, Bucholz KK, Nelson EC, Glowinski AL, et al. (2002) A twin
study of genetic and environmental influences on suicidality in men. Psychol
Med 32: 11–24.
9. Brent DA, Mann JJ (2005) Family genetic studies, suicide, and suicidal behavior.
Am J Med Genet C Semin Med Genet 133C: 13–24.
10. Turecki G (2005) Dissecting the suicide phenotype: the role of impulsive-
aggressive behaviours. J Psychiatry Neurosci 30: 398–408.
11. Brezo J, Klempan T, Turecki G (2008) The genetics of suicide: a critical review
of molecular studies. Psychiatr Clin North Am 31: 179–203.
12. Bondy B, Buettner A, Zill P (2006) Genetics of suicide. Mol Psychiatry 11:
336–351.
13. Perlis RH, Huang J, Purcell S, Fava M, Rush AJ, et al. (2010) Genome-Wide
Association Study of Suicide Attempts in Mood Disorder Patients.
Am J Psychiatry 167: 1499–1507.
14. Perroud N, Uher R, Ng MY, Guipponi M, Hauser J, et al. (2010) Genome-wide
association study of increasing suicidal ideation during antidepressant treatment
in the GENDEP project. Pharmacogenomics J.
15. Laje G, Allen AS, Akula N, Manji H, John Rush A, et al. (2009) Genome-wide
association study of suicidal ideation emerging during citalopram treatment of
depressed outpatients. Pharmacogenet Genomics 19: 666–674.
16. Kohli MA, Salyakina D, Pfennig A, Lucae S, Horstmann S, et al. (2010)
Association of Genetic Variants in the Neurotrophic Receptor-Encoding Gene
NTRK2 and a Lifetime History of Suicide Attempts in Depressed Patients. Arch
Gen Psychiatry 67: 348–359.
17. Rosa AR, Frey BN, Andreazza AC, Cereser KM, Cunha AB, et al. (2006)
Increased serum glial cell line-derived neurotrophic factor immunocontent
during manic and depressive episodes in individuals with bipolar disorder.
Neurosci Lett 407: 146–150.
18. Chen PS, Peng GS, Li G, Yang S, Wu X, et al. (2006) Valproate protects
dopaminergic neurons in midbrain neuron/glia cultures by stimulating the
release of neurotrophic factors from astrocytes. Mol Psychiatry 11: 1116–1125.
19. Otsuki K, Uchida S, Watanuki T, Wakabayashi Y, Fujimoto M, et al. (2008)
Altered expression of neurotrophic factors in patients with major depression.
J Psychiatr Res 42: 1145–1153.
20. Michel TM, Frangou S, Camara S, Thiemeyer D, Jecel J, et al. (2008) Altered
glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of
patients with depressive disorder: a comparative post-mortem study. Eur
Psychiatry 23: 413–420.
21. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, et al. (2009) Association
of the NPAS3 gene and five other loci with response to the antipsychotic
iloperidone identified in a whole genome association study. Mol Psychiatry 14:
804–819.
22. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, et al. (2003)
Altered gene expression of brain-derived neurotrophic factor and receptor
tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry
60: 804–815.
23. Kim B, Kim CY, Hong JP, Kim SY, Lee C, et al. (2008) Brain-derived
neurotrophic factor Val/Met polymorphism and bipolar disorder. Association of
the Met allele with suicidal behavior of bipolar patients. Neuropsychobiology 58:
97–103.
24. Wasserman D, Geijer T, Sokolowski M, Rozanov V, Wasserman J (2006) The
serotonin 1A receptor C(-1019)G polymorphism in relation to suicide attempt.
Behav Brain Funct 2: 14.
25. Cui H, Nishiguchi N, Ivleva E, Yanagi M, Fukutake M, et al. (2008) Association
of RGS2 gene polymorphisms with suicide and increased RGS2 immunoreac-
tivity in the postmortem brain of suicide victims. Neuropsychopharmacology 33:
1537–1544.
GWAS of Suicidal Behaviour in Major Depression
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e20690
26. Shindo S, Yoshioka N (2005) Polymorphisms of the cholecystokinin gene
promoter region in suicide victims in Japan. Forensic Sci Int 150: 85–90.
27. Uher R, Perroud N (2010) Probing the genome to understand suicide.
Am J Psychiatry 167: 1425–1427.
28. Cohen-Woods S, Gaysina D, Craddock N, Farmer A, Gray J, et al. (2009)
Depression Case Control (DeCC) Study fails to support involvement of the
muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major
depressive disorder. Hum Mol Genet 18: 1504–1509.
29. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al. (1990) SCAN.
Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47:
589–593.
30. Farmer A, Breen G, Brewster S, Craddock N, Gill M, et al. (2004) The
Depression Network (DeNT) Study: methodology and sociodemographic
characteristics of the first 470 affected sibling pairs from a large multi-site
linkage genetic study. BMC Psychiatry 4: 42.
31. McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, et al. (2005) Whole
genome linkage scan of recurrent depressive disorder from the depression
network study. Hum Mol Genet 14: 3337–3345.
32. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet 38: 904–909.
33. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, et al. (2010)
Genome-wide association study of major recurrent depression in the U.K.
population. Am J Psychiatry 167: 949–957.
34. Devlin B, Roeder K (1999) Genomic control for association studies. Biometrics
55: 997–1004.
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
36. Dudbridge F, Gusnanto A (2008) Estimation of significance thresholds for
genomewide association scans. Genet Epidemiol 32: 227–234.
37. Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits. Bioinformatics
19: 149–150.
38. Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide
polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74:
765–769.
39. Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the
eigenvalues of a correlation matrix. Heredity 95: 221–227.
40. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, et al. (2010) Genome-
wide association study of recurrent major depressive disorder in two European
case-control cohorts. Mol Psychiatry 15: 589–601.
41. Kunzel HE, Binder EB, Nickel T, Ising M, Fuchs B, et al. (2003)
Pharmacological and nonpharmacological factors influencing hypothalamic-
pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-
patients, measured by the Dex-CRH test. Neuropsychopharmacology 28:
2169–2178.
42. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, et al. (2004)
Polymorphisms in FKBP5 are associated with increased recurrence of depressive
episodes and rapid response to antidepressant treatment. Nat Genet 36:
1319–1325.
43. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, et al. (2004)
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and
design. Control Clin Trials 25: 119–142.
GWAS of Suicidal Behaviour in Major Depression
PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e20690
